For patients with ductal carcinoma in situ, stromal PDGFRb expression could predict radiation benefit, and potentially lead to effective combination therapies.
UCSD and Fore Bio researchers found that patients harboring certain RAS mutations with high MAPK activity may benefit from treatment like Novartis' Mekinist.
Researchers used a framework called Trial Pathfinder to show how data-driven eligibility criteria could make trials more inclusive without altering outcomes.
In a study presented at AACR, immunotherapy responses across 20 cancer types were consistently higher for tumors with TMB of at least 16 somatic mutations per megabase.
Researchers presented interim results from the pilot PEER study of Aromasin, leuprolide, and Keytruda for HR-positive, HER2-negative advanced breast cancer.
The firm presented data at the AACR annual meeting that demonstrates its approach to treating HER2-positive solid cancers with engineered CAR macrophages.
A recent study suggests the lack of diversity in public databases may affect the accuracy of TMB scores and lead to inappropriate treatment for racial minorities.
The autologous, anti-BCMA CAR T-cell therapy may be the first to garner FDA approval for multiple myeloma patients but competing products may soon catch up.
Researchers are increasingly arguing that the tissue-agnostic approval was too broad, and that tumor mutational burden is only a biomarker of response to immunotherapy in a handful of cancer types.
The firm will collect multi-omics data from GBM patients and use its AI platform to home in on biomarkers of response to BPM31510.